X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ORCHID PHARMA LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ORCHID PHARMA LTD DR. REDDYS LAB/
ORCHID PHARMA LTD
 
P/E (TTM) x 32.7 0.1 23,767.1% View Chart
P/BV x 2.7 0.2 1,643.3% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 DR. REDDYS LAB   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs3,397194 1,750.9%   
Low Rs2,56035 7,314.3%   
Sales per share (Unadj.) Rs856.5276.5 309.8%  
Earnings per share (Unadj.) Rs78.0-79.2 -98.4%  
Cash flow per share (Unadj.) Rs139.9-43.5 -322.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.853.9 1,371.7%  
Shares outstanding (eoy) m165.7470.45 235.3%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.50.4 839.6%   
Avg P/E ratio x38.2-1.4 -2,642.9%  
P/CF ratio (eoy) x21.3-2.6 -807.9%  
Price / Book Value ratio x4.02.1 189.6%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6328,067 6,119.5%   
No. of employees `00022.72.8 810.0%   
Total wages/salary Rs m31,0682,527 1,229.4%   
Avg. sales/employee Rs Th6,259.06,956.1 90.0%   
Avg. wages/employee Rs Th1,369.8902.5 151.8%   
Avg. net profit/employee Rs Th569.7-1,993.0 -28.6%   
INCOME DATA
Net Sales Rs m141,96119,477 728.9%  
Other income Rs m1,715407 421.2%   
Total revenues Rs m143,67619,884 722.6%   
Gross profit Rs m24,7221,103 2,242.2%  
Depreciation Rs m10,2662,519 407.5%   
Interest Rs m6345,227 12.1%   
Profit before tax Rs m15,537-6,236 -249.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,965-125 -2,368.2%   
Profit after tax Rs m12,921-5,580 -231.5%  
Gross profit margin %17.45.7 307.6%  
Effective tax rate %19.12.0 950.5%   
Net profit margin %9.1-28.7 -31.8%  
BALANCE SHEET DATA
Current assets Rs m96,83711,014 879.2%   
Current liabilities Rs m84,19932,060 262.6%   
Net working cap to sales %8.9-108.1 -8.2%  
Current ratio x1.20.3 334.8%  
Inventory Days Days7395 77.3%  
Debtors Days Days9834 291.1%  
Net fixed assets Rs m102,55229,440 348.3%   
Share capital Rs m829705 117.7%   
"Free" reserves Rs m121,7922,043 5,962.6%   
Net worth Rs m122,6213,800 3,227.0%   
Long term debt Rs m5,4499,018 60.4%   
Total assets Rs m218,16546,510 469.1%  
Interest coverage x25.5-0.2 -13,207.5%   
Debt to equity ratio x02.4 1.9%  
Sales to assets ratio x0.70.4 155.4%   
Return on assets %6.2-0.8 -817.5%  
Return on equity %10.5-146.9 -7.2%  
Return on capital %12.9-3.7 -345.4%  
Exports to sales %54.637.9 144.2%   
Imports to sales %9.422.6 41.3%   
Exports (fob) Rs m77,5207,378 1,050.7%   
Imports (cif) Rs m13,2744,406 301.3%   
Fx inflow Rs m81,6707,513 1,087.0%   
Fx outflow Rs m26,3555,649 466.6%   
Net fx Rs m55,3151,865 2,966.7%   
CASH FLOW
From Operations Rs m21,4441,682 1,275.1%  
From Investments Rs m-18,404-9,860 186.6%  
From Financial Activity Rs m-3,6926,644 -55.6%  
Net Cashflow Rs m-1,144-1,535 74.5%  

Share Holding

Indian Promoters % 25.5 32.3 78.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.6 117.4%  
FIIs % 35.3 3.3 1,069.7%  
ADR/GDR % 18.5 4.6 402.2%  
Free float % 15.3 55.3 27.7%  
Shareholders   75,885 84,811 89.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Cheap Valuation of PSU Banks and Key Stocks in Action Today(Pre-Open)

NSE PSU Bank Index surged 30% on 25th October 2017-the date when bank recapitalization of Rs 2.1 trillion was announced.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 18, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS